Genomma Lab Internacional, S.A.B. de C.V. Stock

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E. 06:00:00 2024-06-06 pm EDT 5-day change 1st Jan Change
16.66 MXN -4.75% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. -6.25% +17.66%
Sales 2024 * 17.82B 970M Sales 2025 * 19.12B 1.04B Capitalization 15.75B 857M
Net income 2024 * 1.98B 108M Net income 2025 * 2.22B 121M EV / Sales 2024 * 1.08 x
Net Debt 2024 * 3.45B 188M Net Debt 2025 * 2.83B 154M EV / Sales 2025 * 0.97 x
P/E ratio 2024 *
7.57 x
P/E ratio 2025 *
7.67 x
Employees 1,590
Yield 2024 *
-
Yield 2025 *
2.01%
Free-Float 69.81%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment CI
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2023 Earnings Call, Oct 26, 2023
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2023 Earnings Call, Jul 27, 2023
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2023 Earnings Call, Apr 27, 2023
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V. - Analyst/Investor Day
More news

Latest transcript on Genomma Lab Internacional, S.A.B. de C.V.

1 day-4.75%
1 week-6.25%
Current month-6.25%
1 month-3.25%
3 months+18.49%
6 months+21.78%
Current year+17.66%
More quotes
1 week
15.21
Extreme 15.21
18.40
1 month
15.21
Extreme 15.21
18.77
Current year
12.39
Extreme 12.39
18.77
1 year
12.39
Extreme 12.39
18.77
3 years
12.39
Extreme 12.39
23.00
5 years
12.39
Extreme 12.39
24.58
10 years
8.75
Extreme 8.75
37.15
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Founder - 96-10-29
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 70 18-04-17
Founder - 96-10-29
Director/Board Member - 97-12-31
More insiders
Date Price Change Volume
24-06-07 16.66 -4.75% 2,739,133
24-06-06 17.49 -2.24% 3,716,123
24-06-05 17.89 +3.95% 2,358,023
24-06-04 17.21 +9.41% 3,041,136
24-06-03 15.73 -11.48% 2,781,943

End-of-day quote Mexican S.E., June 06, 2024

More quotes
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
16.66 MXN
Average target price
19.5 MXN
Spread / Average Target
+17.05%
Consensus